Dispatch Bio, a biotech startup founded in 2022, officially launched with $216 million in funding, including backing from CAR-T pioneer Carl June. The company’s technology platform, named Flare, delivers a viral vector encoding a universal antigen that tags solid tumor cells, enabling engineered immune cells to target and clear cancer while sparing healthy tissue. The approach addresses key challenges in solid tumor immunotherapy, such as antigen heterogeneity and immune suppression within tumors. Dispatch plans clinical testing next year and aims to expand beyond CAR-T therapies.